Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Abstract Background Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immune-related adverse events (irAEs). Endocrinopathies have reported as one...

Full description

Bibliographic Details
Main Authors: Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yonglong Zhuang, Jia He
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint inhibitors
Endocrine toxicities
FAERS
PD-1/PD-L1
CTLA-4
Monotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0754-2

Internet

http://link.springer.com/article/10.1186/s40425-019-0754-2

Similar Items